// App-Quantinova.ai

1121-253 : RATIONALE AND METHODS OF THE PROSPECTIVE STUDY OF BIOMARKERS, SYMPTOM IMPROVEMENT AND VENTRICULAR REMODELING DURING ENTRESTO THERAPY FOR HEART FAILURE (PROVE-HF) STUDY

Researchers

Presenter

  • James L. Januzzia

Principal Investigators

  • Javed Butlera

  • G. Michael Felkera

  • Emmanuel Fombua

  • Alan Maisela

  • Kevin McCaguea

  • Ileana Pinaa

  • Margaret Prescotta

  • Jerome Riebmana

  • Scott Solomona

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • N/A

Biomarkers

  • B-type natriuretic peptide

  • N-terminal pro b-type natriuretic peptide

Drug/Treatment

  • Sacubitril/valsartan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved